Secondary Hypogonadism Treatment Algorithm by Line of Therapy

Secondary hypogonadism, clomiphene, enclomiphene, and hCG: what these terms mean

"Secondary hypogonadism" (also called hypogonadotropic hypogonadism) describes low testosterone that originates at the hypothalamus or pituitary rather than the testes. This is distinct from primary hypogonadism, where the testes themselves are damaged and LH/FSH rise as the pituitary tries to compensate.

Several drugs discussed below are not interchangeable. Clomiphene citrate is a selective estrogen receptor modulator (SERM) FDA-approved for female ovulatory dysfunction and used off-label in men. Enclomiphene is the trans-isomer of clomiphene, marketed and studied separately for male secondary hypogonadism; its current FDA approval status for this indication is inconsistently described across sources and should be verified against the current FDA label before it is presented to a patient as an approved therapy. Human chorionic gonadotropin (hCG) is a glycoprotein hormone that mimics LH and directly stimulates testicular Leydig cells; it is a biologic product, and compounded versions of hCG have not been consistently available since a 2020 FDA classification change, a detail that is time-sensitive and should be confirmed against current FDA guidance before quoting cost or availability.

Because the testes remain functional in secondary hypogonadism, stimulating the HPG axis with a SERM or hCG can restore endogenous testosterone production and, in many men, maintain spermatogenesis, an option that generally is not available in primary hypogonadism, where the testes cannot respond to stimulation regardless of signal.

Secondary hypogonadism refers to low testosterone accompanied by a low or inappropriately normal LH, reflecting insufficient hypothalamic-pituitary signaling rather than testicular failure. Because the testes remain capable of responding to stimulation, treatment differs fundamentally from primary hypogonadism: reversible contributors such as obesity, opioid use, and hyperprolactinemia are addressed first, fertility-preserving stimulation with a SERM or hCG follows, and exogenous testosterone is reserved as a later option for men who do not need fertility preservation. This staged approach is consistent with the framework in the 2025 European Association of Urology guideline update on male hypogonadism (EAU 2025 update).

Missing the primary-versus-secondary distinction has a real consequence: starting exogenous testosterone in a man who could have responded to a less suppressive alternative shuts down his own HPG axis and can leave him temporarily infertile, sometimes for many months after stopping.

First-line: identify and treat reversible causes before starting a hormone

Before prescribing anything, the reversible contributors should be looked for and treated. The most commonly cited drivers in the literature are obesity, opioid analgesics, glucocorticoids, and poorly controlled type 2 diabetes.

Weight loss can meaningfully raise testosterone in obese men. Published lifestyle-intervention and bariatric-surgery studies have reported testosterone increases ranging from modest (roughly 15-20% with sustained lifestyle-driven weight loss) to large (on the order of several hundred ng/dL after substantial post-surgical weight loss), with bigger gains generally seen in men who lose the most weight. These figures come from specific trials and meta-analyses; the exact magnitude quoted for any one study should be checked against the original publication before being used to counsel an individual patient, since the number depends heavily on baseline BMI, the population studied, and follow-up length.

Opioid-induced androgen deficiency is a well-recognized entity: chronic opioid use suppresses GnRH pulsatility at the hypothalamus. Published prevalence estimates among men on chronic opioid therapy vary widely across studies, so a single precise percentage should not be treated as settled. The practical point that is well supported is directional: opioid dose reduction, rotation, or discontinuation is the recommended first step when feasible, with hormonal therapy considered only if symptoms persist despite that change.

For type 2 diabetes, metabolic optimization (weight loss, improved glycemic control, and in some cases GLP-1 receptor agonist therapy) can indirectly raise testosterone through reduced insulin resistance and adiposity. This is not testosterone therapy. It removes a suppressive input on the HPG axis rather than substituting for it.

The practical decision at this stage is straightforward: if the man is obese, on chronic opioids, or has poorly controlled diabetes, address those first and recheck testosterone and LH after roughly three to six months. A meaningful number of men will no longer meet the diagnostic threshold once the reversible driver is addressed.

Second-line: SERMs or hCG when fertility matters

When first-line measures fail, or testosterone remains low without an identifiable reversible cause, pharmacologic stimulation of the HPG axis is the next consideration, particularly for men who want to preserve current or future fertility.

Clomiphene citrate (commonly dosed in the 25-50 mg/day range in published protocols) blocks estrogen feedback at the hypothalamus, increasing GnRH pulsatility and downstream LH/FSH release. It is inexpensive relative to testosterone gels and generally well tolerated, though reported side effects include visual disturbances in a small minority of patients, mood changes, and occasional breast tenderness. Long-term safety data beyond a few years of use are limited in the published literature, which is itself an evidence gap rather than a reassurance.

Enclomiphene is the isolated trans-isomer of clomiphene and is intended to avoid the longer-acting estrogenic effects attributed to the cis-isomer (zuclomiphene) present in racemic clomiphene. Small trials have reported that enclomiphene raises testosterone while better preserving sperm concentration compared with topical testosterone in similar populations. As noted above, its regulatory status for this specific indication is inconsistently described across sources and needs verification against the current FDA label rather than being taken as settled.

hCG mimics LH and directly stimulates Leydig cells, typically dosed by subcutaneous injection multiple times weekly in published protocols. Lower and higher dose regimens have been studied for their ability to maintain intratesticular testosterone at levels associated with ongoing spermatogenesis, and hCG is sometimes combined with exogenous testosterone in men who want symptomatic benefit while trying to preserve some fertility potential. Guideline language broadly favors hCG (with or without a SERM) over testosterone therapy alone in men who currently desire fertility, though the exact wording and strength of that recommendation should be checked against the current version of the guideline in use, since guidance in this area has been updated as recently as 2025.

Third-line: exogenous testosterone replacement

Exogenous testosterone is generally reserved for men with confirmed secondary hypogonadism who do not need fertility preservation, who have failed or declined SERM/hCG therapy, or who have a permanent hypothalamic-pituitary lesion such as post-surgical hypopituitarism.

A large randomized cardiovascular-safety trial of testosterone gel in men with pre-existing or high cardiovascular risk (published in a major medical journal in 2023) reported no significant increase in major adverse cardiovascular events compared with placebo over roughly three years of follow-up. This was an important and reassuring finding for a long-standing safety question, but the exact hazard ratio and confidence interval should be confirmed against the published trial report before being quoted as a precise figure. A separate, earlier placebo-controlled trial in older men with low testosterone found that one year of transdermal testosterone improved sexual function and some physical measures but did not improve cognitive function, illustrating that testosterone therapy's benefits are domain-specific rather than global.

Formulation options include injectable testosterone (generally the lowest cost per month), topical gels (steadier levels, higher cost), subcutaneous pellets (implanted periodically, avoiding daily dosing), and intranasal testosterone (frequent dosing, with preliminary and still-developing data on fertility preservation). The choice depends on patient preference, cost, insurance coverage, and whether any residual fertility preservation matters. Guideline sources generally advise against testosterone monotherapy in men actively trying to conceive, regardless of formulation, because it suppresses the same HPG axis a SERM or hCG is designed to stimulate.

Monitoring after starting any hormonal therapy

Every patient started on a SERM, hCG, or testosterone for secondary hypogonadism needs structured follow-up. In broad terms, published guidance converges on checking testosterone, LH/FSH (where relevant to the therapy), hematocrit, and PSA (in men old enough for PSA to be clinically meaningful) at intervals after starting therapy, then periodically thereafter. Elevated hematocrit is a recognized reason to hold or adjust testosterone therapy, though the exact threshold used varies by guideline version and should be confirmed locally rather than assumed.

For men on a SERM, estradiol is often monitored because excess estrogen conversion can cause gynecomastia and may prompt a dose reduction or a switch between clomiphene and enclomiphene. Bone density monitoring is reasonable to consider in men with prolonged, untreated hypogonadism, since low testosterone over time is associated with reduced bone density, though the specific duration threshold that should trigger a DEXA scan is a matter of clinical judgment rather than a single fixed number across all guidelines.

Testosterone therapy is not first-line for most men with secondary hypogonadism; correcting the underlying driver, where one is identifiable, comes first in essentially every major guideline framework reviewed here.

When a red flag means referral, not a prescription

Some findings should stop a primary-care or telehealth pathway and prompt specialist referral rather than empiric hormone therapy.

A markedly elevated prolactin level raises concern for a prolactin-secreting pituitary tumor and warrants pituitary MRI and endocrinology or neurosurgery input; even a mildly elevated prolactin combined with visual field changes, headaches, or galactorrhea deserves imaging. Men younger than roughly 30 with secondary hypogonadism and no obvious reversible cause should generally have pituitary imaging considered, to exclude a congenital GnRH deficiency syndrome or a pituitary tumor.

Iron overload, elevated ferritin with elevated transferrin saturation, raises concern for hemochromatosis, which can deposit iron in the pituitary and cause a treatable form of secondary hypogonadism through phlebotomy rather than hormone replacement. Recent literature on hemochromatosis mechanisms, including iron-driven cellular injury pathways, underscores why this cause should be actively screened for rather than assumed absent (hemochromatosis mechanisms review, 2024).

Multiple pituitary hormone deficiencies, low testosterone alongside low cortisol, hypothyroidism, or growth hormone deficiency, suggest panhypopituitarism and require comprehensive endocrine evaluation before testosterone replacement, because starting testosterone without recognizing coexisting adrenal insufficiency can precipitate an adrenal crisis.

A decision framework: what changes the recommended starting point

The table below is not a substitute for individualized diagnosis or dosing. It is meant to make explicit which patient-level facts should change where a clinician or telehealth prescriber starts, and which facts should stop the algorithm and trigger referral instead.

What is established, what is plausible, and what is not settled

Established: the core distinction between primary and secondary hypogonadism based on LH behavior, the general principle that reversible causes should be addressed before hormonal therapy, and the fact that exogenous testosterone suppresses the HPG axis and can reduce fertility while a SERM or hCG is designed to stimulate it instead.

Plausible but not settled with precision: the exact size of testosterone increases attributable to weight loss in a given patient, the exact prevalence of opioid-induced androgen deficiency, and the precise comparative fertility outcomes of clomiphene versus enclomiphene versus hCG, since much of this evidence comes from small trials or specific populations that do not automatically generalize.

Not established from the material reviewed here: a single universally agreed dosing protocol for SERMs or hCG in secondary hypogonadism, or a single fixed monitoring interval and hematocrit threshold that applies identically across every current guideline version. Anyone using this article to guide a specific dose or monitoring schedule should confirm current numbers against the guideline version their prescriber is actually using, since guidance in this space has been revised as recently as 2025.